Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments

DARU, Journal of Pharmaceutical Sciences

Volumn 21, Issue 1, 2013, Pages

  Nikfar, Shekoufeh ^a,b   Kebriaeezadeh, Abbas ^a   Dinarvand, Rassoul ^a   Abdollahi, Mohammad ^a,c   Sahraian, Mohammad Ali ^d   Henry, David ^e   Akbari Sari, Ali ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Cost Effectiveness; Decision analysis; Economic evaluation; Interferon beta; Markov model; Modeling; Switching

Indexed keywords

BETA1A INTERFERON; BIOSIMILAR AGENT; INTERFERON BETA SERINE; PLACEBO;

ADULT; ARTICLE; CLINICAL STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROSS-SECTIONAL STUDY; DECISION MAKING; DECISION TREE; DISEASE COURSE; ECONOMIC EVALUATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; INCOME; IRAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SYMPTOM; WORLD HEALTH ORGANIZATION;

EID: 84879874565     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/2008-2231-21-50     Document Type: Article

References (81)

1. Multiple sclerosis: risk factors and their interactions. Disanto G, Morahan JM, Ramagopalan SV, CNS Neurol Disord Drug Targets 2012 11 5 545 555 10.2174/187152712801661266 22583442
2. Multiple sclerosis International federation http://www.msif.org
3. High nationwide prevalence of multiple sclerosis in Sweden. Ahlgren C, Odén A, Lycke J, Mult Scler 2011 17 8 901 908 10.1177/1352458511403794 21459810
4. Multiple sclerosis in time and space-geographic clues to cause. Kurtzke JF, J Neurovirol 2000 6 2 134 S140 10871801
5. Multiple sclerosis: a risk factor analysis Iran. Yousefi Pour GA, Ali Reza Rasekhi AR, Arch Iran Med 2002 5 3 191 193
6. Multiple sclerosis: report on 200 cases from Iran. Kalanie H, Gharagozli K, Kalanie AR, Mult Scler 2003 9 36 38 10.1191/1352458503ms887oa 12617266 (Pubitemid 36253694)
7. Multiple sclerosis in Isfahan, Iran. Saadatnia M, Etemadifar M, Maghzi AH, Int Rev Neurobiol 2007 79 357 375 17531850
8. Multiple sclerosis in East-Azerbaijan, north west Iran. Hashemilar M, Savadi Ouskui D, Farhoudi M, Ayromlou H, Asadollahi A, Neurol Asia 2011 16 2 127 131
9. Epidemiology of Multiple sclerosis in Mazandaran in 2007 (in Persian). Abedini M, Habibi Saravi R, Zarvani A, Farahmand A, J Mazand Univ Med Sci 2008 18 66 82 87
10. Multiple sclerosis: Geoepidemiology, genetics and the environment. Milo R, Kahana E, Autoimmun Rev 2010 9 387 A394 10.1016/j.autrev.2009.11.010 19932200
11. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H, Eur Neurol 2010 64 331 336 10.1159/000321649 21071949
12. Prevalence of multiple sclerosis in Isfahan, Iran. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F, Neuroepidemiology 2006 27 39 44 10.1159/000094235 16804333 (Pubitemid 44114410)
13. A 20-year incidence trend (1989-2008) and point prevalence (March 20, 2009) of multiple sclerosis in Tehran, Iran: a population-based study. Elhami SR, Mohammad K, Sahraian MA, Eftekhar H, Neuroepidemiology 2011 36 3 141 147 10.1159/000324708 21508646
14. Epidemiology, clinical trend and prognosis of multiple sclerosis in 203 patients of MS clinic in Shahid Mostafa Khomeini hospital in 2002 (in Persian). Nabavi M, Poorfarzam S, Ghasemi H, Tehran Univ Med J 2006 64 7 90 97
15. Prevalence of multiple sclerosis in north east of Iran. Ghandehari K, Riasi HR, Nourian A, Boroumand AR, Mult Scler 2010 16 12 1525 1526 10.1177/1352458510372150 20534643
16. Epidemiology of multiple sclerosis in Tehran: a three year study. Ghabaae M, Qelichnia Omrani H, Roostaeizadeh M, Tehran Univ Med J 2007 65 5 74 77
17. Multiple sclerosis: a study of 318 cases. Ale-Yasin H, Sarai A, Alaeddini F, Ansarian E, Lotfi J, Sanati H, Arch Iran Med 2002 5 1 24 27 (Pubitemid 34591498)
18. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. Bell C, Graham J, Earnshaw S, Oleen-Burkey M, Castelli-Haley J, Johnson K, J Manag Care Pharm 2007 13 3 245 261 17407391 (Pubitemid 46730893)
19. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Nuijten MJ, Hutton J, Value Health 2002 5 1 44 54 10.1046/j.1524-4733.2002.51052.x 11873383 (Pubitemid 34160370)
20. Statistical center of Iran http://www.amar.org.ir
21. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Nikfar S, Rahimi R, Rezaie A, Abdollahi M, Arch Med Sci 2010 6 2 236 244 22371753
22. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Nikfar S, Rahimi R, Abdollahi M, Clin Ther 2010 2 11 1871 1888
23. A systematic review on the efficacy of interferon beta in relapsing remitting multiple sclerosis; comparison of different formulations. Nikfar S, Rahimi R, Abdollahi M, Inter J Pharmacol 2010 6 5 638 644
24. International diffusion of new health technologies: a ten-country analysis of six health technologies. Packer C, Simpson S, Stevens A, Int J Technol Assess Health Care 2006 22 4 419 428 16984674 (Pubitemid 44622961)
25. European medicines agency, EMEA http://www.ema.europa.eu/ema/index
26. United States of America Food and drug administration, US-FDA http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index
27. Diffusion of interferon beta in Iran and its utilization in Tehran. Palesh M, Jonsson PM, Jamshidi H, Wettermark B, Tomson G, Fredrikson S, Pharmacoepidemiol Drug Saf 2008 17 9 934 941 10.1002/pds.1621 18509835
28. Iranian Food and Drug Organization http://fdo.behdasht.gov.ir
29. Biosimilars; a unique opportunity for Iran national health sector and national pharmaceutical industry. Cheraghali AM, Daru 2012 20 1 35 10.1186/2008-2231-20-35 23351613
30. World Health Organization, WHO, http://www.who.int
31. Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M, BMC Int Health Hum Rights 2005 5 1 5 10.1186/1472-698X-5-5 15885139 (Pubitemid 41014259)
32. A model for developing a decision support system to simulate national drug policy indicators. Abdollahiasl A, Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Arch Med Sci 2011 7 5 744 746 22291816
33. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. Cheraghali AM, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, Asadi A, Bahrami A, East Mediterr Health J 2004 10 3 406 415 16212218 (Pubitemid 41404104)
34. Cost and utilization study of antidotes: An Iranian experience. Nikfar S, Khatibi M, Abdollahiasl A, Abdollahi M, Int J Pharmacol 2011 7 1 46 49
35. A new model for decision analysis in economic evaluations of switchable health interventions. Nikfar S, J Med Hypotheses Ideas 2012 6 12 15 10.1016/j.jmhi.2012.03.008
36. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Kobelt G, Jonsson L, Fredrikson S, Eur J Health Econ 2003 4 1 50 59 10.1007/s10198-002-0163-0 15609169 (Pubitemid 36457057)
37. Economic evaluation of Avonex (interferon beta-1a) in patients following a single demyelinating event. Iskedjian M, Walker JH, Gray T, Vicente C, Einarson TR, Gehshan A, Mult Scler 2005 11 5 542 551 10.1191/1352458505ms1211oa 16193892 (Pubitemid 41387699)
38. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis: first estimates. Bose U, Ladkani D, Burrell A, Sharief M, J Med Econ 2001 4 207 219 10.3111/200104207219
39. A cost-utility analysis of interferon beta for multiple sclerosis. Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D, Health Technol Assess 1998 2 4 ii 54 9919458
40. A cost utility model of beta-interferon in the treatment of relapsing-remitting multiple sclerosis. Phillips CJ, Gilmour L, Gale R, Palmer M, J Med Econ 2001 4 35 50 10.3111/200104035050 (Pubitemid 32367058)
41. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. Chilcott J, McCabe C, Tappenden P, O'Hagan A, Cooper NJ, Abrams K, Claxton K, Miller DH, Cost Effectiveness of Multiple Sclerosis Therapies Study Group, BMJ 2003 326 7388 522 10.1136/bmj.326.7388.522 12623909
42. Decision modelling for health economic evaluation. Briggs A, Claxton K, Sculpher M, Handbooks in health economic evaluation Oxford: Oxford University Press vol. 1 2006
43. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Kurtzke JF, Neurology 1983 33 11 1444 1452 10.1212/WNL.33.11.1444 6685237 (Pubitemid 14237132)
44. Estimation of social discount rate for Iran. Abdoli G, Eco Res Rev 2009 10 135 156
45. Estimation of private and social time preferences for health in northern Tanzania. Robberstad B, Soc Sci Med 2005 61 7 1597 1607 10.1016/j.socscimed. 2005.03.013 15885866 (Pubitemid 41001303)
46. Generalized cost-effectiveness analysis: a guide. Baltussen R, Adam T, Tan Torres T, Hutubessy R, Acharya A, Evans DB, Murray CJL, World Health Organization. Global programme on evidence for health policy Geneva: World Health Organization (WHO) 2002
47. The natural history of multiple sclerosis: a geographically-based study. I. Clinical course and disability. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC, Brain 1989 112 133 146 10.1093/brain/112.1.133 2917275 (Pubitemid 19056478)
48. Contribution of relapses to disability in multiple sclerosis. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N, J Neurol 2008 255 2 280 287 10.1007/s00415-008-0743-8 18204919
49. Survival and cause of death in multiple sclerosis: a prospective population-based study. Hirst C, Swingler R, Compston DA, Ben-Shlomo Y, Robertson NP, J Neurol Neurosurg Psychiatry 2008 79 1016 1021 10.1136/jnnp.2007.127332 18303108
50. Health outcomes in economic evaluation: the QALY and utilities. Whitehead SJ, Ali S, Br Med Bull 2010 96 5 21 10.1093/bmb/ldq033 21037243
51. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis. Tappenden P, Chilcott JB, Eggington S, Oakley J, McCabe C, Health Technol Assess 2004 8 27 http://www.hta.ac.uk/ fullmono/mon827.pdf
52. National organization for civil registration: Survival data of Iran http://www.sabteahval.ir
53. Natural history of secondary-progressive multiple sclerosis. Tremlett H, Zhao Y, Devonshire V, Mult Scler 2008 14 314 324 10.1177/1352458507084264 18208898 (Pubitemid 351676426)
54. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Tremlett H, Zhao Y, Devonshire V, J Neurol 2009 256 374 381 10.1007/s00415-009-0039-7 19308306
55. Placebo-controlled multicentre andomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS, Lancet 1998 352 9139 1491 1497 10.1016/S0140-6736(98)10039-9 9820296 (Pubitemid 28512924)
56. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group, Clinical results. Neurology 2001 56 11 1496 1504
57. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE III, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. Ann Neurol 1996 39 3 285 294 10.1002/ana.410390304 8602746 (Pubitemid 26100751)
58. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS, Neurology 2004 63 10 1788 1795 15557491 (Pubitemid 39532370)
59. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, Lancet 1998 352 9139 1498 1504 10.1016/S0140-6736(98)03334-0 9820297 (Pubitemid 28512925)
60. Multicenter, randomized, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, Sandberg-Wollheim M, Soelberg Sørensen P, J Neurol Neurosurg Psychiatry 2004 75 5 706 710 10.1136/jnnp.2003.010090 15090564 (Pubitemid 38526680)
61. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ, Neurology 2003 60 1 44 51 10.1212/WNL.60.1.44 12525716 (Pubitemid 36070642)
62. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFN, β Multiple Sclerosis Study Group, Neurology 1993 43 4 655 661 8469318
63. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D, Neurology 2006 67 944 953 10.1212/01.wnl.0000237994.95410. ce 17000959 (Pubitemid 44454583)
64. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, Investigators of the 16-year Long-Term Follow-Up Study, J Neurol Neurosurg Psychiatry 2010 81 907 912 10.1136/jnnp.2009.204123 20562430
65. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Rudick RA, Lee JC, Cutter GR, Miller DM, Bourdette D, Weinstock-Guttman B, Hyde R, Zhang H, You X, Arch Neurol 2010 67 11 1329 1335 10.1001/archneurol.2010.150 20625068
66. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment. Phillips CJ, CNS Drugs 2004 18 9 561 574 10.2165/00023210-200418090-00002 15222773 (Pubitemid 38951779)
67. O'Brien B, Multiple sclerosis London: Office of Health Economics 1987
68. Cost effectiveness of beta interferons and glatiramer acetate in the management of multiple sclerosis. Tappenden P, Chilcott J, O'Hagan A, McCabe C, Final Report to the National Institute for Clinical Excellence London: National Institute for Clinical Excellence (NICE) 2001
69. Cost-effectiveness analyses of natalizumab (Tysabri®) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J, PharmacoEconomics 2008 26 7 617 627 10.2165/00019053-200826070-00008 18563952 (Pubitemid 351876727)
70. Iran ministry of health and medical education, Tariff of healthcare services in public and private sectors in Iran (2012) Tehran: Iran ministry of health and medical education press 2012
71. National Organization of Transportation http://upto.ir
72. The friction cost method for measuring indirect costs of disease. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L, J Health Econ 1995 14 171 189 10.1016/0167-6296(94)00044-5 10154656
73. Bayesian analysis of unemployment duration data in presence of right and interval censoring. Ganjali M, Baghfalaki T, JRSS 2012 5 1 17 32
74. Asian Productivity Organization, APO productivity data book 2012 Tokyo: Keio university press INC 2012
75. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ, J Neurol Neurosurg Psychiatry 2005 76 58 63 10.1136/jnnp.2003.017897 15607996 (Pubitemid 40013492)
76. Strom BL, Kimmel SE, Textbook of pharmacoepidemiology Chichester, West Sussex: John Willey & Sons 2006
77. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Bobes J, Cañas F, Rejas J, Mackell J, Prog Neuropsychopharmacol Biol Psychiatry 2004 28 1287 1297 10.1016/j.pnpbp.2004.06.017 15588755 (Pubitemid 39592926)
78. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM, J Manag Care Pharm 2009 15 7 543 555 19739877
79. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ, J Neurol Neurosurg Psychiatry 2005 76 1 58 63 10.1136/jnnp.2003.017897 15607996 (Pubitemid 40013492)
80. The effects of clinical interventions on health-related quality of life in multiple sclerosis: a meta-analysis. Kuspinar A, Rodriguez AM, Mayo NE, Mult Scler 2012 18 12 1686 1704 10.1177/1352458512445201 23235779
81. European Medicines Agency (EMEA), EMEA Guideline on Similar Biological Medicinal Products, CHMP/437/04. [ http://www.emea.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003517.pdf].